menu
    • menu

    Company profile for AlgoTherapeutix

    NEW Drugs in Dev: 3
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AlgoTherapeutix develops therapeutic solutions for complex pain through topical re-positioning of validated drug actives. Our first program, ATx-001, targets severe pain of the hands and feet caused by Chemotherapy-Induced Peripheral Neuropathy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlgoTherapeutixFrance Flag
    Country
    Country
    France
    Address
    Address
    49 rue des Nouvelles 92150 Suresnes
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://algotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/algotherapeutix/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NetraMark and AlgoTx Partner for ATX01 Clinical Trial Design
    NetraMark and AlgoTx Partner for ATX01 Clinical Trial Design

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122385/0/en/NetraMark-Signs-Contract-with-AlgoTx-to-Enhance-Clinical-Trial-Design-for-ATX01.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    AlgoTx Reports Ph 2 ACT Trial Results For ATX01 In CIPN
    AlgoTx Reports Ph 2 ACT Trial Results For ATX01 In CIPN

    18 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/18/3027514/0/en/AlgoTx-Announces-Results-of-its-Phase-2-ACT-Trial-of-ATX01-in-Chemotherapy-Induced-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    18 Feb 2025
    Share Share
    AlgoTx Completes Phase II Trial Of ATX01 In Neuropathy
    AlgoTx Completes Phase II Trial Of ATX01 In Neuropathy

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2951875/0/en/AlgoTx-Announces-Last-Patient-Last-Visit-in-International-Phase-II-Trial-of-ATX01-in-Chemotherapy-Induced-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    Algo Announces Initiation of Global Phase 2 Clinical Trial of ATX01
    Algo Announces Initiation of Global Phase 2 Clinical Trial of ATX01

    01 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220901005014/en

    BUSINESSWIRE
    01 Sep 2022
    Share Share
    AlgoTherapeutix Completes Phase I for ATX01, Poised for Phase II in 2022
    AlgoTherapeutix Completes Phase I for ATX01, Poised for Phase II in 2022

    17 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211117005624/en

    BUSINESSWIRE
    17 Nov 2021
    Share Share
    AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical DevPt of ATX01
    AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical DevPt of ATX01

    15 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201214005352/en

    BUSINESSWIRE
    15 Dec 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search